nodes	percent_of_prediction	percent_of_DWPC	metapath
Buprenorphine—CYP2A6—Fluorouracil—head and neck cancer	0.104	0.137	CbGbCtD
Buprenorphine—ABCG2—Fluorouracil—head and neck cancer	0.0959	0.127	CbGbCtD
Buprenorphine—CYP2D6—Hydroxyurea—head and neck cancer	0.0853	0.113	CbGbCtD
Buprenorphine—ABCG2—Docetaxel—head and neck cancer	0.0732	0.0968	CbGbCtD
Buprenorphine—CYP3A7—Docetaxel—head and neck cancer	0.0541	0.0715	CbGbCtD
Buprenorphine—CYP3A7-CYP3A51P—Docetaxel—head and neck cancer	0.0541	0.0715	CbGbCtD
Buprenorphine—CYP2C8—Fluorouracil—head and neck cancer	0.0511	0.0675	CbGbCtD
Buprenorphine—CYP3A5—Docetaxel—head and neck cancer	0.0406	0.0536	CbGbCtD
Buprenorphine—CYP1A2—Fluorouracil—head and neck cancer	0.0396	0.0523	CbGbCtD
Buprenorphine—CYP2C9—Fluorouracil—head and neck cancer	0.0356	0.0471	CbGbCtD
Buprenorphine—ABCB1—Vinblastine—head and neck cancer	0.032	0.0423	CbGbCtD
Buprenorphine—CYP2D6—Vinblastine—head and neck cancer	0.0302	0.0399	CbGbCtD
Buprenorphine—ABCB1—Docetaxel—head and neck cancer	0.0264	0.0349	CbGbCtD
Buprenorphine—CYP3A4—Vinblastine—head and neck cancer	0.0192	0.0254	CbGbCtD
Buprenorphine—CYP3A4—Docetaxel—head and neck cancer	0.0158	0.0209	CbGbCtD
Buprenorphine—Slurred speech—Fluorouracil—head and neck cancer	0.00274	0.0199	CcSEcCtD
Buprenorphine—Ileus—Vinblastine—head and neck cancer	0.00264	0.0191	CcSEcCtD
Buprenorphine—Application site reaction—Fluorouracil—head and neck cancer	0.00262	0.019	CcSEcCtD
Buprenorphine—Numbness—Vinblastine—head and neck cancer	0.00226	0.0163	CcSEcCtD
Buprenorphine—Balance disorder—Fluorouracil—head and neck cancer	0.00224	0.0163	CcSEcCtD
Buprenorphine—Sensory loss—Vinblastine—head and neck cancer	0.00216	0.0156	CcSEcCtD
Buprenorphine—Heartburn—Fluorouracil—head and neck cancer	0.00178	0.0129	CcSEcCtD
Buprenorphine—Numbness—Fluorouracil—head and neck cancer	0.00148	0.0107	CcSEcCtD
Buprenorphine—Sensory loss—Fluorouracil—head and neck cancer	0.00142	0.0103	CcSEcCtD
Buprenorphine—Disorientation—Hydroxyurea—head and neck cancer	0.00138	0.01	CcSEcCtD
Buprenorphine—Pharyngolaryngeal pain—Docetaxel—head and neck cancer	0.00131	0.0095	CcSEcCtD
Buprenorphine—Laryngeal pain—Docetaxel—head and neck cancer	0.0013	0.00941	CcSEcCtD
Buprenorphine—Dysarthria—Fluorouracil—head and neck cancer	0.0013	0.0094	CcSEcCtD
Buprenorphine—Heartburn—Docetaxel—head and neck cancer	0.00129	0.00932	CcSEcCtD
Buprenorphine—Inflammation—Fluorouracil—head and neck cancer	0.00127	0.00916	CcSEcCtD
Buprenorphine—Ileus—Docetaxel—head and neck cancer	0.00125	0.00906	CcSEcCtD
Buprenorphine—Dermatitis contact—Fluorouracil—head and neck cancer	0.00121	0.00878	CcSEcCtD
Buprenorphine—Face oedema—Hydroxyurea—head and neck cancer	0.00119	0.00865	CcSEcCtD
Buprenorphine—Angina pectoris—Vinblastine—head and neck cancer	0.00114	0.00827	CcSEcCtD
Buprenorphine—Coma—Fluorouracil—head and neck cancer	0.00112	0.00812	CcSEcCtD
Buprenorphine—Breast disorder—Hydroxyurea—head and neck cancer	0.00112	0.0081	CcSEcCtD
Buprenorphine—Rigors—Docetaxel—head and neck cancer	0.00108	0.00786	CcSEcCtD
Buprenorphine—Euphoric mood—Fluorouracil—head and neck cancer	0.00105	0.00764	CcSEcCtD
Buprenorphine—Depression—Vinblastine—head and neck cancer	0.00104	0.00755	CcSEcCtD
Buprenorphine—Disorientation—Fluorouracil—head and neck cancer	0.000996	0.00721	CcSEcCtD
Buprenorphine—Drug interaction—Docetaxel—head and neck cancer	0.000955	0.00692	CcSEcCtD
Buprenorphine—Infestation NOS—Hydroxyurea—head and neck cancer	0.000954	0.00691	CcSEcCtD
Buprenorphine—Infestation—Hydroxyurea—head and neck cancer	0.000954	0.00691	CcSEcCtD
Buprenorphine—Hypoaesthesia—Vinblastine—head and neck cancer	0.000934	0.00677	CcSEcCtD
Buprenorphine—Pharyngitis—Vinblastine—head and neck cancer	0.000932	0.00675	CcSEcCtD
Buprenorphine—Inflammation—Docetaxel—head and neck cancer	0.000913	0.00661	CcSEcCtD
Buprenorphine—Lethargy—Fluorouracil—head and neck cancer	0.000909	0.00658	CcSEcCtD
Buprenorphine—Hepatobiliary disease—Hydroxyurea—head and neck cancer	0.000902	0.00653	CcSEcCtD
Buprenorphine—Respiratory failure—Docetaxel—head and neck cancer	0.000902	0.00653	CcSEcCtD
Buprenorphine—Osteoarthritis—Fluorouracil—head and neck cancer	0.000891	0.00645	CcSEcCtD
Buprenorphine—Blood pressure increased—Docetaxel—head and neck cancer	0.000886	0.00642	CcSEcCtD
Buprenorphine—Injection site reaction—Docetaxel—head and neck cancer	0.000881	0.00638	CcSEcCtD
Buprenorphine—Influenza like illness—Docetaxel—head and neck cancer	0.00086	0.00623	CcSEcCtD
Buprenorphine—Hallucination—Hydroxyurea—head and neck cancer	0.000852	0.00617	CcSEcCtD
Buprenorphine—Dry skin—Fluorouracil—head and neck cancer	0.000817	0.00591	CcSEcCtD
Buprenorphine—Nasopharyngitis—Fluorouracil—head and neck cancer	0.000797	0.00577	CcSEcCtD
Buprenorphine—Muscular weakness—Fluorouracil—head and neck cancer	0.000786	0.00569	CcSEcCtD
Buprenorphine—Angiopathy—Hydroxyurea—head and neck cancer	0.000777	0.00563	CcSEcCtD
Buprenorphine—Dysphagia—Fluorouracil—head and neck cancer	0.00077	0.00558	CcSEcCtD
Buprenorphine—Chills—Hydroxyurea—head and neck cancer	0.000768	0.00556	CcSEcCtD
Buprenorphine—Ill-defined disorder—Vinblastine—head and neck cancer	0.000758	0.00549	CcSEcCtD
Buprenorphine—Angina pectoris—Fluorouracil—head and neck cancer	0.00075	0.00543	CcSEcCtD
Buprenorphine—Erythema—Hydroxyurea—head and neck cancer	0.000745	0.0054	CcSEcCtD
Buprenorphine—Malaise—Vinblastine—head and neck cancer	0.000737	0.00534	CcSEcCtD
Buprenorphine—Vertigo—Vinblastine—head and neck cancer	0.000734	0.00532	CcSEcCtD
Buprenorphine—Upper respiratory tract infection—Fluorouracil—head and neck cancer	0.000716	0.00518	CcSEcCtD
Buprenorphine—Convulsion—Vinblastine—head and neck cancer	0.000708	0.00513	CcSEcCtD
Buprenorphine—Hypertension—Vinblastine—head and neck cancer	0.000706	0.00511	CcSEcCtD
Buprenorphine—Ill-defined disorder—Hydroxyurea—head and neck cancer	0.000692	0.00501	CcSEcCtD
Buprenorphine—Discomfort—Vinblastine—head and neck cancer	0.000687	0.00498	CcSEcCtD
Buprenorphine—Hot flush—Docetaxel—head and neck cancer	0.000687	0.00498	CcSEcCtD
Buprenorphine—Infestation NOS—Fluorouracil—head and neck cancer	0.000687	0.00497	CcSEcCtD
Buprenorphine—Infestation—Fluorouracil—head and neck cancer	0.000687	0.00497	CcSEcCtD
Buprenorphine—Menopausal symptoms—Docetaxel—head and neck cancer	0.000681	0.00493	CcSEcCtD
Buprenorphine—Visual disturbance—Docetaxel—head and neck cancer	0.000679	0.00491	CcSEcCtD
Buprenorphine—Malaise—Hydroxyurea—head and neck cancer	0.000672	0.00487	CcSEcCtD
Buprenorphine—Conjunctivitis—Fluorouracil—head and neck cancer	0.000667	0.00483	CcSEcCtD
Buprenorphine—Urinary tract infection—Fluorouracil—head and neck cancer	0.000667	0.00483	CcSEcCtD
Buprenorphine—Lethargy—Docetaxel—head and neck cancer	0.000656	0.00475	CcSEcCtD
Buprenorphine—Convulsion—Hydroxyurea—head and neck cancer	0.000646	0.00468	CcSEcCtD
Buprenorphine—Sinusitis—Fluorouracil—head and neck cancer	0.000644	0.00466	CcSEcCtD
Buprenorphine—Pain in extremity—Docetaxel—head and neck cancer	0.000643	0.00466	CcSEcCtD
Buprenorphine—Anorexia—Vinblastine—head and neck cancer	0.000636	0.0046	CcSEcCtD
Buprenorphine—Migraine—Docetaxel—head and neck cancer	0.000633	0.00458	CcSEcCtD
Buprenorphine—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—head and neck cancer	0.00063	0.00456	CcSEcCtD
Buprenorphine—Discomfort—Hydroxyurea—head and neck cancer	0.000627	0.00454	CcSEcCtD
Buprenorphine—Rhinitis—Fluorouracil—head and neck cancer	0.000618	0.00447	CcSEcCtD
Buprenorphine—Hypoaesthesia—Fluorouracil—head and neck cancer	0.000613	0.00444	CcSEcCtD
Buprenorphine—Pharyngitis—Fluorouracil—head and neck cancer	0.000612	0.00443	CcSEcCtD
Buprenorphine—Oedema—Hydroxyurea—head and neck cancer	0.000608	0.00441	CcSEcCtD
Buprenorphine—Infection—Hydroxyurea—head and neck cancer	0.000604	0.00438	CcSEcCtD
Buprenorphine—Paraesthesia—Vinblastine—head and neck cancer	0.000599	0.00434	CcSEcCtD
Buprenorphine—Dehydration—Docetaxel—head and neck cancer	0.000598	0.00433	CcSEcCtD
Buprenorphine—Nervous system disorder—Hydroxyurea—head and neck cancer	0.000597	0.00432	CcSEcCtD
Buprenorphine—Skin disorder—Hydroxyurea—head and neck cancer	0.000591	0.00428	CcSEcCtD
Buprenorphine—Dry skin—Docetaxel—head and neck cancer	0.000589	0.00427	CcSEcCtD
Buprenorphine—Orthostatic hypotension—Docetaxel—head and neck cancer	0.000587	0.00425	CcSEcCtD
Buprenorphine—Abdominal pain upper—Docetaxel—head and neck cancer	0.000587	0.00425	CcSEcCtD
Buprenorphine—Breast disorder—Docetaxel—head and neck cancer	0.000581	0.00421	CcSEcCtD
Buprenorphine—Anorexia—Hydroxyurea—head and neck cancer	0.00058	0.0042	CcSEcCtD
Buprenorphine—Decreased appetite—Vinblastine—head and neck cancer	0.00058	0.0042	CcSEcCtD
Buprenorphine—Cramp muscle—Docetaxel—head and neck cancer	0.000579	0.00419	CcSEcCtD
Buprenorphine—Nasopharyngitis—Docetaxel—head and neck cancer	0.000575	0.00416	CcSEcCtD
Buprenorphine—Constipation—Vinblastine—head and neck cancer	0.00057	0.00413	CcSEcCtD
Buprenorphine—Pain—Vinblastine—head and neck cancer	0.00057	0.00413	CcSEcCtD
Buprenorphine—Alanine aminotransferase increased—Docetaxel—head and neck cancer	0.000567	0.00411	CcSEcCtD
Buprenorphine—Dysphagia—Docetaxel—head and neck cancer	0.000556	0.00402	CcSEcCtD
Buprenorphine—Feeling abnormal—Vinblastine—head and neck cancer	0.00055	0.00398	CcSEcCtD
Buprenorphine—Bronchospasm—Docetaxel—head and neck cancer	0.000547	0.00396	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Vinblastine—head and neck cancer	0.000545	0.00395	CcSEcCtD
Buprenorphine—Dyspnoea—Hydroxyurea—head and neck cancer	0.000542	0.00393	CcSEcCtD
Buprenorphine—Angina pectoris—Docetaxel—head and neck cancer	0.000541	0.00392	CcSEcCtD
Buprenorphine—Somnolence—Hydroxyurea—head and neck cancer	0.000541	0.00392	CcSEcCtD
Buprenorphine—Erythema—Fluorouracil—head and neck cancer	0.000537	0.00389	CcSEcCtD
Buprenorphine—Dyspepsia—Hydroxyurea—head and neck cancer	0.000535	0.00388	CcSEcCtD
Buprenorphine—Decreased appetite—Hydroxyurea—head and neck cancer	0.000529	0.00383	CcSEcCtD
Buprenorphine—Abdominal pain—Vinblastine—head and neck cancer	0.000527	0.00382	CcSEcCtD
Buprenorphine—Gastrointestinal disorder—Hydroxyurea—head and neck cancer	0.000525	0.0038	CcSEcCtD
Buprenorphine—Fatigue—Hydroxyurea—head and neck cancer	0.000524	0.0038	CcSEcCtD
Buprenorphine—Pain—Hydroxyurea—head and neck cancer	0.00052	0.00377	CcSEcCtD
Buprenorphine—Constipation—Hydroxyurea—head and neck cancer	0.00052	0.00377	CcSEcCtD
Buprenorphine—Vision blurred—Fluorouracil—head and neck cancer	0.000506	0.00366	CcSEcCtD
Buprenorphine—Weight decreased—Docetaxel—head and neck cancer	0.000503	0.00364	CcSEcCtD
Buprenorphine—Feeling abnormal—Hydroxyurea—head and neck cancer	0.000501	0.00363	CcSEcCtD
Buprenorphine—Infestation NOS—Docetaxel—head and neck cancer	0.000496	0.00359	CcSEcCtD
Buprenorphine—Infestation—Docetaxel—head and neck cancer	0.000496	0.00359	CcSEcCtD
Buprenorphine—Hypersensitivity—Vinblastine—head and neck cancer	0.000491	0.00356	CcSEcCtD
Buprenorphine—Conjunctivitis—Docetaxel—head and neck cancer	0.000482	0.00349	CcSEcCtD
Buprenorphine—Body temperature increased—Hydroxyurea—head and neck cancer	0.000481	0.00348	CcSEcCtD
Buprenorphine—Asthenia—Vinblastine—head and neck cancer	0.000479	0.00347	CcSEcCtD
Buprenorphine—Hepatobiliary disease—Docetaxel—head and neck cancer	0.000469	0.00339	CcSEcCtD
Buprenorphine—Convulsion—Fluorouracil—head and neck cancer	0.000465	0.00337	CcSEcCtD
Buprenorphine—Chest pain—Fluorouracil—head and neck cancer	0.000457	0.00331	CcSEcCtD
Buprenorphine—Myalgia—Fluorouracil—head and neck cancer	0.000457	0.00331	CcSEcCtD
Buprenorphine—Diarrhoea—Vinblastine—head and neck cancer	0.000456	0.00331	CcSEcCtD
Buprenorphine—Discomfort—Fluorouracil—head and neck cancer	0.000451	0.00327	CcSEcCtD
Buprenorphine—Hypersensitivity—Hydroxyurea—head and neck cancer	0.000448	0.00325	CcSEcCtD
Buprenorphine—Rhinitis—Docetaxel—head and neck cancer	0.000446	0.00323	CcSEcCtD
Buprenorphine—Hypoaesthesia—Docetaxel—head and neck cancer	0.000443	0.00321	CcSEcCtD
Buprenorphine—Confusional state—Fluorouracil—head and neck cancer	0.000441	0.0032	CcSEcCtD
Buprenorphine—Pharyngitis—Docetaxel—head and neck cancer	0.000441	0.0032	CcSEcCtD
Buprenorphine—Dizziness—Vinblastine—head and neck cancer	0.000441	0.00319	CcSEcCtD
Buprenorphine—Urinary tract disorder—Docetaxel—head and neck cancer	0.000439	0.00318	CcSEcCtD
Buprenorphine—Oedema peripheral—Docetaxel—head and neck cancer	0.000438	0.00317	CcSEcCtD
Buprenorphine—Anaphylactic shock—Fluorouracil—head and neck cancer	0.000438	0.00317	CcSEcCtD
Buprenorphine—Oedema—Fluorouracil—head and neck cancer	0.000438	0.00317	CcSEcCtD
Buprenorphine—Connective tissue disorder—Docetaxel—head and neck cancer	0.000437	0.00317	CcSEcCtD
Buprenorphine—Asthenia—Hydroxyurea—head and neck cancer	0.000436	0.00316	CcSEcCtD
Buprenorphine—Urethral disorder—Docetaxel—head and neck cancer	0.000436	0.00316	CcSEcCtD
Buprenorphine—Infection—Fluorouracil—head and neck cancer	0.000435	0.00315	CcSEcCtD
Buprenorphine—Nervous system disorder—Fluorouracil—head and neck cancer	0.000429	0.00311	CcSEcCtD
Buprenorphine—Visual impairment—Docetaxel—head and neck cancer	0.000429	0.0031	CcSEcCtD
Buprenorphine—Tachycardia—Fluorouracil—head and neck cancer	0.000427	0.00309	CcSEcCtD
Buprenorphine—Vomiting—Vinblastine—head and neck cancer	0.000424	0.00307	CcSEcCtD
Buprenorphine—Headache—Vinblastine—head and neck cancer	0.000418	0.00303	CcSEcCtD
Buprenorphine—Anorexia—Fluorouracil—head and neck cancer	0.000417	0.00302	CcSEcCtD
Buprenorphine—Diarrhoea—Hydroxyurea—head and neck cancer	0.000416	0.00301	CcSEcCtD
Buprenorphine—Eye disorder—Docetaxel—head and neck cancer	0.000416	0.00301	CcSEcCtD
Buprenorphine—Cardiac disorder—Docetaxel—head and neck cancer	0.000413	0.00299	CcSEcCtD
Buprenorphine—Flushing—Docetaxel—head and neck cancer	0.000413	0.00299	CcSEcCtD
Buprenorphine—Hypotension—Fluorouracil—head and neck cancer	0.000409	0.00296	CcSEcCtD
Buprenorphine—Angiopathy—Docetaxel—head and neck cancer	0.000404	0.00292	CcSEcCtD
Buprenorphine—Dizziness—Hydroxyurea—head and neck cancer	0.000402	0.00291	CcSEcCtD
Buprenorphine—Immune system disorder—Docetaxel—head and neck cancer	0.000402	0.00291	CcSEcCtD
Buprenorphine—Mediastinal disorder—Docetaxel—head and neck cancer	0.000401	0.0029	CcSEcCtD
Buprenorphine—Chills—Docetaxel—head and neck cancer	0.000399	0.00289	CcSEcCtD
Buprenorphine—Musculoskeletal discomfort—Fluorouracil—head and neck cancer	0.000399	0.00289	CcSEcCtD
Buprenorphine—Nausea—Vinblastine—head and neck cancer	0.000396	0.00287	CcSEcCtD
Buprenorphine—Insomnia—Fluorouracil—head and neck cancer	0.000396	0.00287	CcSEcCtD
Buprenorphine—Paraesthesia—Fluorouracil—head and neck cancer	0.000393	0.00285	CcSEcCtD
Buprenorphine—Dyspnoea—Fluorouracil—head and neck cancer	0.00039	0.00283	CcSEcCtD
Buprenorphine—Mental disorder—Docetaxel—head and neck cancer	0.00039	0.00282	CcSEcCtD
Buprenorphine—Somnolence—Fluorouracil—head and neck cancer	0.000389	0.00282	CcSEcCtD
Buprenorphine—Erythema—Docetaxel—head and neck cancer	0.000387	0.0028	CcSEcCtD
Buprenorphine—Malnutrition—Docetaxel—head and neck cancer	0.000387	0.0028	CcSEcCtD
Buprenorphine—Vomiting—Hydroxyurea—head and neck cancer	0.000387	0.0028	CcSEcCtD
Buprenorphine—Dyspepsia—Fluorouracil—head and neck cancer	0.000385	0.00279	CcSEcCtD
Buprenorphine—Rash—Hydroxyurea—head and neck cancer	0.000384	0.00278	CcSEcCtD
Buprenorphine—Dermatitis—Hydroxyurea—head and neck cancer	0.000383	0.00278	CcSEcCtD
Buprenorphine—Headache—Hydroxyurea—head and neck cancer	0.000381	0.00276	CcSEcCtD
Buprenorphine—Decreased appetite—Fluorouracil—head and neck cancer	0.000381	0.00276	CcSEcCtD
Buprenorphine—Dysgeusia—Docetaxel—head and neck cancer	0.000379	0.00275	CcSEcCtD
Buprenorphine—Gastrointestinal disorder—Fluorouracil—head and neck cancer	0.000378	0.00274	CcSEcCtD
Buprenorphine—Back pain—Docetaxel—head and neck cancer	0.000375	0.00271	CcSEcCtD
Buprenorphine—Pain—Fluorouracil—head and neck cancer	0.000374	0.00271	CcSEcCtD
Buprenorphine—Muscle spasms—Docetaxel—head and neck cancer	0.000372	0.0027	CcSEcCtD
Buprenorphine—Nausea—Hydroxyurea—head and neck cancer	0.000361	0.00262	CcSEcCtD
Buprenorphine—Feeling abnormal—Fluorouracil—head and neck cancer	0.000361	0.00261	CcSEcCtD
Buprenorphine—Urticaria—Fluorouracil—head and neck cancer	0.000348	0.00252	CcSEcCtD
Buprenorphine—Syncope—Docetaxel—head and neck cancer	0.000347	0.00251	CcSEcCtD
Buprenorphine—Body temperature increased—Fluorouracil—head and neck cancer	0.000346	0.00251	CcSEcCtD
Buprenorphine—Palpitations—Docetaxel—head and neck cancer	0.000342	0.00248	CcSEcCtD
Buprenorphine—Loss of consciousness—Docetaxel—head and neck cancer	0.00034	0.00246	CcSEcCtD
Buprenorphine—Cough—Docetaxel—head and neck cancer	0.000338	0.00245	CcSEcCtD
Buprenorphine—Convulsion—Docetaxel—head and neck cancer	0.000336	0.00243	CcSEcCtD
Buprenorphine—Hypertension—Docetaxel—head and neck cancer	0.000334	0.00242	CcSEcCtD
Buprenorphine—Arthralgia—Docetaxel—head and neck cancer	0.00033	0.00239	CcSEcCtD
Buprenorphine—Myalgia—Docetaxel—head and neck cancer	0.00033	0.00239	CcSEcCtD
Buprenorphine—Chest pain—Docetaxel—head and neck cancer	0.00033	0.00239	CcSEcCtD
Buprenorphine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—head and neck cancer	0.000327	0.00237	CcSEcCtD
Buprenorphine—Hypersensitivity—Fluorouracil—head and neck cancer	0.000323	0.00234	CcSEcCtD
Buprenorphine—Dry mouth—Docetaxel—head and neck cancer	0.000322	0.00233	CcSEcCtD
Buprenorphine—Confusional state—Docetaxel—head and neck cancer	0.000319	0.00231	CcSEcCtD
Buprenorphine—Anaphylactic shock—Docetaxel—head and neck cancer	0.000316	0.00229	CcSEcCtD
Buprenorphine—Oedema—Docetaxel—head and neck cancer	0.000316	0.00229	CcSEcCtD
Buprenorphine—Infection—Docetaxel—head and neck cancer	0.000314	0.00227	CcSEcCtD
Buprenorphine—Shock—Docetaxel—head and neck cancer	0.000311	0.00225	CcSEcCtD
Buprenorphine—Nervous system disorder—Docetaxel—head and neck cancer	0.00031	0.00224	CcSEcCtD
Buprenorphine—Pruritus—Fluorouracil—head and neck cancer	0.00031	0.00224	CcSEcCtD
Buprenorphine—Tachycardia—Docetaxel—head and neck cancer	0.000308	0.00223	CcSEcCtD
Buprenorphine—Skin disorder—Docetaxel—head and neck cancer	0.000307	0.00222	CcSEcCtD
Buprenorphine—Anorexia—Docetaxel—head and neck cancer	0.000301	0.00218	CcSEcCtD
Buprenorphine—Diarrhoea—Fluorouracil—head and neck cancer	0.0003	0.00217	CcSEcCtD
Buprenorphine—Hypotension—Docetaxel—head and neck cancer	0.000295	0.00214	CcSEcCtD
Buprenorphine—Dizziness—Fluorouracil—head and neck cancer	0.00029	0.0021	CcSEcCtD
Buprenorphine—Musculoskeletal discomfort—Docetaxel—head and neck cancer	0.000288	0.00209	CcSEcCtD
Buprenorphine—Insomnia—Docetaxel—head and neck cancer	0.000286	0.00207	CcSEcCtD
Buprenorphine—Paraesthesia—Docetaxel—head and neck cancer	0.000284	0.00206	CcSEcCtD
Buprenorphine—Dyspnoea—Docetaxel—head and neck cancer	0.000282	0.00204	CcSEcCtD
Buprenorphine—Somnolence—Docetaxel—head and neck cancer	0.000281	0.00203	CcSEcCtD
Buprenorphine—Vomiting—Fluorouracil—head and neck cancer	0.000278	0.00202	CcSEcCtD
Buprenorphine—Dyspepsia—Docetaxel—head and neck cancer	0.000278	0.00201	CcSEcCtD
Buprenorphine—Rash—Fluorouracil—head and neck cancer	0.000276	0.002	CcSEcCtD
Buprenorphine—Dermatitis—Fluorouracil—head and neck cancer	0.000276	0.002	CcSEcCtD
Buprenorphine—Decreased appetite—Docetaxel—head and neck cancer	0.000275	0.00199	CcSEcCtD
Buprenorphine—Headache—Fluorouracil—head and neck cancer	0.000274	0.00199	CcSEcCtD
Buprenorphine—Gastrointestinal disorder—Docetaxel—head and neck cancer	0.000273	0.00198	CcSEcCtD
Buprenorphine—Fatigue—Docetaxel—head and neck cancer	0.000272	0.00197	CcSEcCtD
Buprenorphine—Pain—Docetaxel—head and neck cancer	0.00027	0.00196	CcSEcCtD
Buprenorphine—Constipation—Docetaxel—head and neck cancer	0.00027	0.00196	CcSEcCtD
Buprenorphine—Feeling abnormal—Docetaxel—head and neck cancer	0.00026	0.00189	CcSEcCtD
Buprenorphine—Nausea—Fluorouracil—head and neck cancer	0.00026	0.00188	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Docetaxel—head and neck cancer	0.000258	0.00187	CcSEcCtD
Buprenorphine—Abdominal pain—Docetaxel—head and neck cancer	0.00025	0.00181	CcSEcCtD
Buprenorphine—Body temperature increased—Docetaxel—head and neck cancer	0.00025	0.00181	CcSEcCtD
Buprenorphine—Hypersensitivity—Docetaxel—head and neck cancer	0.000233	0.00169	CcSEcCtD
Buprenorphine—Asthenia—Docetaxel—head and neck cancer	0.000227	0.00164	CcSEcCtD
Buprenorphine—Pruritus—Docetaxel—head and neck cancer	0.000224	0.00162	CcSEcCtD
Buprenorphine—Diarrhoea—Docetaxel—head and neck cancer	0.000216	0.00157	CcSEcCtD
Buprenorphine—Dizziness—Docetaxel—head and neck cancer	0.000209	0.00151	CcSEcCtD
Buprenorphine—Vomiting—Docetaxel—head and neck cancer	0.000201	0.00146	CcSEcCtD
Buprenorphine—Rash—Docetaxel—head and neck cancer	0.000199	0.00144	CcSEcCtD
Buprenorphine—Dermatitis—Docetaxel—head and neck cancer	0.000199	0.00144	CcSEcCtD
Buprenorphine—Headache—Docetaxel—head and neck cancer	0.000198	0.00143	CcSEcCtD
Buprenorphine—Nausea—Docetaxel—head and neck cancer	0.000188	0.00136	CcSEcCtD
Buprenorphine—OPRL1—Signaling by GPCR—HRAS—head and neck cancer	4.8e-05	0.000457	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—head and neck cancer	4.75e-05	0.000452	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—YAP1—head and neck cancer	4.74e-05	0.00045	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—UROD—head and neck cancer	4.71e-05	0.000448	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—YAP1—head and neck cancer	4.71e-05	0.000448	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—DPYD—head and neck cancer	4.68e-05	0.000445	CbGpPWpGaD
Buprenorphine—OPRL1—GPCR downstream signaling—AKT1—head and neck cancer	4.67e-05	0.000444	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—IL2—head and neck cancer	4.62e-05	0.000439	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—CCND1—head and neck cancer	4.5e-05	0.000428	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—YAP1—head and neck cancer	4.44e-05	0.000422	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—TYMS—head and neck cancer	4.37e-05	0.000416	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—PTEN—head and neck cancer	4.34e-05	0.000413	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	4.33e-05	0.000412	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—GSTM1—head and neck cancer	4.32e-05	0.000411	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—head and neck cancer	4.29e-05	0.000409	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling by GPCR—AKT1—head and neck cancer	4.24e-05	0.000403	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—NAT2—head and neck cancer	4.21e-05	0.0004	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—head and neck cancer	4.15e-05	0.000394	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—GPX1—head and neck cancer	4.14e-05	0.000394	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—CYP1A1—head and neck cancer	4.1e-05	0.00039	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—VEGFA—head and neck cancer	3.92e-05	0.000373	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—STAT3—head and neck cancer	3.88e-05	0.00037	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	3.87e-05	0.000368	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism of lipids and lipoproteins—CYP1A1—head and neck cancer	3.83e-05	0.000364	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	3.77e-05	0.000359	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—head and neck cancer	3.74e-05	0.000356	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—MAPK3—head and neck cancer	3.71e-05	0.000353	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—DPYD—head and neck cancer	3.69e-05	0.000351	CbGpPWpGaD
Buprenorphine—OPRD1—GPCR downstream signaling—IL2—head and neck cancer	3.67e-05	0.000349	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—NAT2—head and neck cancer	3.64e-05	0.000347	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK3—head and neck cancer	3.54e-05	0.000337	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—MAPK1—head and neck cancer	3.53e-05	0.000336	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—EGFR—head and neck cancer	3.53e-05	0.000336	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—YAP1—head and neck cancer	3.5e-05	0.000333	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—TYMS—head and neck cancer	3.46e-05	0.000329	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	3.45e-05	0.000329	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism of lipids and lipoproteins—CYP1A1—head and neck cancer	3.42e-05	0.000325	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—GSTM1—head and neck cancer	3.42e-05	0.000325	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—head and neck cancer	3.37e-05	0.000321	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—head and neck cancer	3.37e-05	0.000321	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—IL2—head and neck cancer	3.34e-05	0.000317	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—GPX1—head and neck cancer	3.27e-05	0.000311	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—NAT2—head and neck cancer	3.25e-05	0.000309	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—CYP1A1—head and neck cancer	3.24e-05	0.000308	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR downstream signaling—IL2—head and neck cancer	3.22e-05	0.000306	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—DPYD—head and neck cancer	3.2e-05	0.000304	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—NAT2—head and neck cancer	3.17e-05	0.000302	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	3.15e-05	0.0003	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—head and neck cancer	3.12e-05	0.000297	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—PIK3CA—head and neck cancer	3.06e-05	0.000291	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—YAP1—head and neck cancer	3.03e-05	0.000288	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—NAT2—head and neck cancer	2.99e-05	0.000285	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—NAT2—head and neck cancer	2.97e-05	0.000282	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—TP53—head and neck cancer	2.96e-05	0.000282	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—TYMS—head and neck cancer	2.93e-05	0.000279	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—IL2—head and neck cancer	2.93e-05	0.000278	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—head and neck cancer	2.92e-05	0.000278	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—TYMS—head and neck cancer	2.91e-05	0.000277	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—GSTM1—head and neck cancer	2.9e-05	0.000276	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—GSTM1—head and neck cancer	2.87e-05	0.000273	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—NOTCH1—head and neck cancer	2.86e-05	0.000272	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—DPYD—head and neck cancer	2.85e-05	0.000271	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—HRAS—head and neck cancer	2.84e-05	0.00027	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—head and neck cancer	2.83e-05	0.000269	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—DPYD—head and neck cancer	2.78e-05	0.000265	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—GPX1—head and neck cancer	2.78e-05	0.000264	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—GPX1—head and neck cancer	2.75e-05	0.000262	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—CYP1A1—head and neck cancer	2.75e-05	0.000262	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—CYP1A1—head and neck cancer	2.73e-05	0.000259	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR downstream signaling—IL2—head and neck cancer	2.72e-05	0.000259	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—YAP1—head and neck cancer	2.71e-05	0.000257	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	2.69e-05	0.000256	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—MAPK3—head and neck cancer	2.68e-05	0.000255	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—TYMS—head and neck cancer	2.67e-05	0.000254	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—head and neck cancer	2.66e-05	0.000253	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	2.66e-05	0.000253	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—YAP1—head and neck cancer	2.64e-05	0.000251	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—GSTM1—head and neck cancer	2.63e-05	0.000251	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—DPYD—head and neck cancer	2.62e-05	0.00025	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—DPYD—head and neck cancer	2.6e-05	0.000247	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—MAPK1—head and neck cancer	2.55e-05	0.000243	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—EGFR—head and neck cancer	2.55e-05	0.000243	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—NAT2—head and neck cancer	2.53e-05	0.000241	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—GPX1—head and neck cancer	2.52e-05	0.00024	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—NOTCH1—head and neck cancer	2.51e-05	0.000239	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—AKT1—head and neck cancer	2.5e-05	0.000238	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—CYP1A1—head and neck cancer	2.5e-05	0.000238	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—YAP1—head and neck cancer	2.49e-05	0.000237	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—IL2—head and neck cancer	2.47e-05	0.000235	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—YAP1—head and neck cancer	2.47e-05	0.000235	CbGpPWpGaD
Buprenorphine—OPRD1—GPCR downstream signaling—PIK3CA—head and neck cancer	2.44e-05	0.000232	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—PTGS2—head and neck cancer	2.44e-05	0.000232	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—head and neck cancer	2.39e-05	0.000227	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—MAPK3—head and neck cancer	2.35e-05	0.000224	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	2.28e-05	0.000217	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—MAPK1—head and neck cancer	2.24e-05	0.000213	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—EGFR—head and neck cancer	2.24e-05	0.000213	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—DPYD—head and neck cancer	2.22e-05	0.000211	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—PIK3CA—head and neck cancer	2.21e-05	0.000211	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR downstream signaling—PIK3CA—head and neck cancer	2.14e-05	0.000203	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—PTEN—head and neck cancer	2.13e-05	0.000202	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—NOTCH1—head and neck cancer	2.12e-05	0.000202	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—YAP1—head and neck cancer	2.11e-05	0.000201	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—TYMS—head and neck cancer	2.1e-05	0.0002	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—GSTM1—head and neck cancer	2.08e-05	0.000198	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—HRAS—head and neck cancer	2.05e-05	0.000195	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	2.03e-05	0.000193	CbGpPWpGaD
Buprenorphine—OPRD1—GPCR downstream signaling—AKT1—head and neck cancer	1.99e-05	0.000189	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—GPX1—head and neck cancer	1.99e-05	0.000189	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—MAPK3—head and neck cancer	1.99e-05	0.000189	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	1.99e-05	0.000189	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—IL2—head and neck cancer	1.97e-05	0.000187	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—CYP1A1—head and neck cancer	1.97e-05	0.000187	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—NAT2—head and neck cancer	1.96e-05	0.000186	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—PIK3CA—head and neck cancer	1.94e-05	0.000185	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—PTGS2—head and neck cancer	1.93e-05	0.000183	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—CCND1—head and neck cancer	1.92e-05	0.000183	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—MAPK1—head and neck cancer	1.89e-05	0.00018	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—EGFR—head and neck cancer	1.89e-05	0.00018	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	1.85e-05	0.000176	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—PTEN—head and neck cancer	1.85e-05	0.000176	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—TYMS—head and neck cancer	1.82e-05	0.000173	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—AKT1—head and neck cancer	1.81e-05	0.000172	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR downstream signaling—PIK3CA—head and neck cancer	1.81e-05	0.000172	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—GSTM1—head and neck cancer	1.8e-05	0.000171	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—HRAS—head and neck cancer	1.8e-05	0.000171	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	1.77e-05	0.000169	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR downstream signaling—AKT1—head and neck cancer	1.75e-05	0.000166	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—IL2—head and neck cancer	1.73e-05	0.000164	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—GPX1—head and neck cancer	1.72e-05	0.000164	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—DPYD—head and neck cancer	1.72e-05	0.000163	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—CYP1A1—head and neck cancer	1.71e-05	0.000162	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—CCND1—head and neck cancer	1.68e-05	0.00016	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—PTEN—head and neck cancer	1.68e-05	0.00016	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—VEGFA—head and neck cancer	1.67e-05	0.000159	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—STAT3—head and neck cancer	1.66e-05	0.000158	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—PIK3CA—head and neck cancer	1.64e-05	0.000156	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—PTGS2—head and neck cancer	1.64e-05	0.000156	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—YAP1—head and neck cancer	1.63e-05	0.000155	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—PTEN—head and neck cancer	1.63e-05	0.000155	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—TYMS—head and neck cancer	1.63e-05	0.000155	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—PTGS2—head and neck cancer	1.62e-05	0.000154	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	1.62e-05	0.000154	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—GSTM1—head and neck cancer	1.61e-05	0.000153	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—TYMS—head and neck cancer	1.59e-05	0.000151	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—AKT1—head and neck cancer	1.59e-05	0.000151	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	1.58e-05	0.000151	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—MAPK3—head and neck cancer	1.58e-05	0.000151	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—GSTM1—head and neck cancer	1.57e-05	0.000149	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—GPX1—head and neck cancer	1.54e-05	0.000146	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—CYP1A1—head and neck cancer	1.52e-05	0.000145	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—HRAS—head and neck cancer	1.52e-05	0.000144	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—MAPK1—head and neck cancer	1.51e-05	0.000143	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—EGFR—head and neck cancer	1.51e-05	0.000143	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—GPX1—head and neck cancer	1.5e-05	0.000143	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—PIK3CA—head and neck cancer	1.5e-05	0.000143	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—TYMS—head and neck cancer	1.49e-05	0.000142	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—CYP1A1—head and neck cancer	1.49e-05	0.000141	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—PTGS2—head and neck cancer	1.49e-05	0.000141	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—TYMS—head and neck cancer	1.48e-05	0.000141	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—GSTM1—head and neck cancer	1.48e-05	0.000141	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR downstream signaling—AKT1—head and neck cancer	1.48e-05	0.00014	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—VEGFA—head and neck cancer	1.47e-05	0.00014	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—GSTM1—head and neck cancer	1.46e-05	0.000139	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—IL2—head and neck cancer	1.46e-05	0.000139	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—STAT3—head and neck cancer	1.45e-05	0.000138	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—PTEN—head and neck cancer	1.43e-05	0.000136	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—CCND1—head and neck cancer	1.42e-05	0.000135	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—GPX1—head and neck cancer	1.41e-05	0.000135	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—PTEN—head and neck cancer	1.41e-05	0.000134	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—GPX1—head and neck cancer	1.4e-05	0.000133	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	1.4e-05	0.000133	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—CYP1A1—head and neck cancer	1.4e-05	0.000133	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—MAPK3—head and neck cancer	1.39e-05	0.000132	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—CYP1A1—head and neck cancer	1.39e-05	0.000132	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	1.38e-05	0.000131	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—PTEN—head and neck cancer	1.37e-05	0.000131	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—AKT1—head and neck cancer	1.34e-05	0.000128	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—MAPK1—head and neck cancer	1.32e-05	0.000126	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—EGFR—head and neck cancer	1.32e-05	0.000126	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—PIK3CA—head and neck cancer	1.31e-05	0.000124	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—PTEN—head and neck cancer	1.3e-05	0.000123	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—TYMS—head and neck cancer	1.27e-05	0.00012	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—TP53—head and neck cancer	1.27e-05	0.00012	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—GSTM1—head and neck cancer	1.25e-05	0.000119	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	1.25e-05	0.000119	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—VEGFA—head and neck cancer	1.24e-05	0.000118	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—STAT3—head and neck cancer	1.23e-05	0.000117	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—AKT1—head and neck cancer	1.23e-05	0.000117	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—HRAS—head and neck cancer	1.21e-05	0.000115	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—GPX1—head and neck cancer	1.2e-05	0.000114	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—CYP1A1—head and neck cancer	1.19e-05	0.000113	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—PIK3CA—head and neck cancer	1.19e-05	0.000113	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—MAPK3—head and neck cancer	1.17e-05	0.000112	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—PTGS2—head and neck cancer	1.17e-05	0.000111	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—PIK3CA—head and neck cancer	1.15e-05	0.000109	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	1.14e-05	0.000109	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—MAPK1—head and neck cancer	1.12e-05	0.000106	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—EGFR—head and neck cancer	1.12e-05	0.000106	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—TP53—head and neck cancer	1.11e-05	0.000106	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—AKT1—head and neck cancer	1.07e-05	0.000102	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—HRAS—head and neck cancer	1.06e-05	0.000101	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—PTEN—head and neck cancer	1.02e-05	9.72e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—PTGS2—head and neck cancer	1.01e-05	9.65e-05	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—PIK3CA—head and neck cancer	1.01e-05	9.57e-05	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—PIK3CA—head and neck cancer	9.97e-06	9.48e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—TYMS—head and neck cancer	9.77e-06	9.3e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	9.75e-06	9.27e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—PIK3CA—head and neck cancer	9.69e-06	9.22e-05	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—AKT1—head and neck cancer	9.68e-06	9.21e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—GSTM1—head and neck cancer	9.66e-06	9.19e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—TP53—head and neck cancer	9.38e-06	8.92e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—AKT1—head and neck cancer	9.37e-06	8.91e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—GPX1—head and neck cancer	9.25e-06	8.8e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—CYP1A1—head and neck cancer	9.16e-06	8.71e-05	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—PIK3CA—head and neck cancer	9.14e-06	8.69e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—PTGS2—head and neck cancer	9.06e-06	8.61e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—HRAS—head and neck cancer	8.97e-06	8.53e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—PTEN—head and neck cancer	8.85e-06	8.42e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—PTGS2—head and neck cancer	8.84e-06	8.41e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—PTGS2—head and neck cancer	8.33e-06	7.92e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—PTGS2—head and neck cancer	8.26e-06	7.86e-05	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—AKT1—head and neck cancer	8.22e-06	7.82e-05	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—AKT1—head and neck cancer	8.15e-06	7.75e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—AKT1—head and neck cancer	7.92e-06	7.53e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—PTEN—head and neck cancer	7.9e-06	7.51e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—PTEN—head and neck cancer	7.71e-06	7.33e-05	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—AKT1—head and neck cancer	7.47e-06	7.1e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—PTEN—head and neck cancer	7.26e-06	6.91e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—PIK3CA—head and neck cancer	7.21e-06	6.86e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—PTEN—head and neck cancer	7.2e-06	6.85e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—PTGS2—head and neck cancer	7.06e-06	6.71e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—PIK3CA—head and neck cancer	6.24e-06	5.94e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—PTEN—head and neck cancer	6.15e-06	5.85e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—AKT1—head and neck cancer	5.89e-06	5.6e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—PIK3CA—head and neck cancer	5.57e-06	5.3e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—PTGS2—head and neck cancer	5.45e-06	5.18e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—PIK3CA—head and neck cancer	5.44e-06	5.17e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—PIK3CA—head and neck cancer	5.12e-06	4.87e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—AKT1—head and neck cancer	5.1e-06	4.85e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—PIK3CA—head and neck cancer	5.08e-06	4.83e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—PTEN—head and neck cancer	4.75e-06	4.52e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—AKT1—head and neck cancer	4.55e-06	4.33e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—AKT1—head and neck cancer	4.44e-06	4.23e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—PIK3CA—head and neck cancer	4.34e-06	4.13e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—AKT1—head and neck cancer	4.19e-06	3.98e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—AKT1—head and neck cancer	4.15e-06	3.95e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—AKT1—head and neck cancer	3.55e-06	3.37e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—PIK3CA—head and neck cancer	3.35e-06	3.19e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—AKT1—head and neck cancer	2.74e-06	2.6e-05	CbGpPWpGaD
